LIST OF ABSTRACTS AND PRESENTING AUTHORS


Vyšlo v časopise: Čes-slov Pediat 2009; 64 (4): 162-168.

MAIN LECTURE

  • 1. Population genetics of cystic fibrosis and the EuroCareCF Patient Registry Project: Implications for neonatal screening (review)

Macek M. Jr.

OPENING LECTURE

  • 2. From suspicion to diagnosis in children with inborn errors of metabolism

Zeman J.

SESSION 1:

NEWBORN SCREENING FOR INHERITED METABOLIC DISORDERS – EXPANDED METABOLIC SCREENING BY TANDEM MASS SPECTROMETRY

  • 3. Quality assurance program for MS/MS analysis in newborn screening and metabolic diagnosis

Lukacs Z.

  • 4. Spectrum of medium chain acyl CoA dehydrogenase (MCAD) mutations identified from newborn screening of 1.14 million ethnically diverse infants

Oerton J.

  • 5. Screening for defects of peroxisomal ß-oxidation

Janzen N.

  • 6. The impact of a second tier blood-spot methylmalonic acid (MMA) using tandem mass spectrometry (MS/MS) on routine newborn screening for IEM

Ranieri E.

  • 7. Italian guidelines for expanded newborn screening using tandem mass spectrometry

Antonozzi I.

  • 8. Expanded newborn screening for metabolic disorders by tandem mass spectrometry in Italy: current status

Cassanello M.

  • 9. Improving newborn screening performance: the Mayo Clinic experience (2004–2008)

Matern D.

POSTERS

  • 10. Diet therapy of galactosemia

Mitish M.

  • 11. Development and validation of a fast quantitative method for plasma, serum and urine dimethylarginines analysis using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)

Di Gangi I. M.

  • 12. Egypt experience implementing a pilot newborn screening program using tandem mass spectrometry

Hassan F.

  • 13. NeoBase non-derivatized MS/MS assay for amino acids, free carnitine, acylcarnitines and succinylacetone: analytical and clinical performance

Huusko J.

  • 14. Characterization of newborns with transient elevation of C3-carnitine

Chang H.-Y.

  • 15. LCHAD deficiency – the most frequent fatty acid oxidation disorder in newborn screening in the Czech Republic

Chrastina P.

  • 16. Frequency of homocystinuria due to cystathionine beta-synthase deficiency in the Czech Republic: implications for neonatal screening

Kozich V.

  • 17. Screening test for enzyme defects in the second part of purine de novo synthesis

Kratschmerova H.

  • 18. Identification of a novel FAH large deletion mutation in a Korean neonate with hereditary tyrosinemia type 1

Lee Y.-W.

  • 19. New biotinidase assay for plate readers

Lerch A.

  • 20. Improved newborn population screening for classical homocystinuria

Lindner M.

  • 21. Biotinidase assay for neonatal biotinidase deficiency screening

Mattsson P.

  • 22. Selective screening of urine’s organic acids

Novikova I.

  • 23. Phenylketonuria in the era of neonatal screening in the Czech Republic, physician’s view

Pazdirkova R.

  • 24. Development of an enhanced screening strategy for classical galactosaemia in the Republic of Ireland

Roche G.

  • 25. Newborn screening for tyrosinemia I, simultaneous versus separate quantitation of succinylacetone

Sander J.

  • 26. Quantitation of amino acids in dried blood spots by iTRAQ®reagent derivatization reaction and LC/MS/MS analysis

Sasaki T. A.

  • 27. Value of tandem mass spectrometry in the diagnosis of organic acidemias

Selim L.

  • 28. Amino acid and acylcarnitine profile testing in newborns by tandem mass spectrometry. An institutional experience by Acibadem Labmed Clinical Laboratories

Serteser M.

  • 29. Evaluation of the commercially available Chromsystems Newborn Screening Kit (non derivatised) for the measurement of acylcarnitines and amino acids

Stopsack M.

  • 30. Screening of newborns and older children for inborn errors of metabolism by tandem mass spectrometry in Nuevo Leon, Mexico

Torres M. R.

  • 31. Development of an automated galactose-1-phosphate uridyl transferase (GALT) assay for newborn screening of classical galactosemia

Vaisanen V.

SESSION 2:

NEWBORN SCREENING FOR LYSOSOMAL STORAGE DISEASES

  • 32. Fluorimetry and mass spectrometry for the determination of lysosomal enzyme activities in dried blood – possibilities for neonatal screening

Lukacs Z.

  • 33. Newborn screening for Pompe disease in Taiwan

Hwu W.-L.

  • 34. Krabbe disease screening in New York State

Orsini J. J.

  • 35. CDC’s quality control program for lysosomal storage disorder newborn screening

De Jesus V. R.

  • 36. Pilot study for neonatal screening for Fabry disease

Colon C.

POSTERS

  • 37. The application of activity ratio in screening for Pompe disease using florescence substrate

Hsu L.-W.

  • 38. Plasma chitotriosidase activity in children with lysosomal storage disorder

Sheth J.

  • 39. Optimization of α-L-iduronidase activity assay in dried bloodspots by tandem mass spectrometry

Zhang K.

SESSION 3:

NEWBORN SCREENING FOR CONGENITAL HYPOTHYROIDISM

  • 40. Screening for congenital hypothyroidism – new evidence towards a European consensus?

Krude H.

  • 41. Thyroid screening in mothers of children from the Neonatal Thyroid Screening (NTS) Program

Stoeva I.

  • 42. The Italian National Register of Infants with Congenital Hypothyroidism: surveillance, research and prevention of the disease

Olivieri A.

  • 43. Congenital hypothyroidism in Czech population: current approach to diagnosis and follow-up

Al Taji E.

  • 44. High incidence of permanent and transient congenital hypothyroidism in premature babies

Chen H.-Ch.

POSTERS

  • 45. Neonatal thyroid screening in the Republic of Macedonia (2003–2008)

Anastasovska V.

  • 46. Robust and standardised Neonatal hTSH EIA and FEIA assays from Ani Labsystems

Carrard G.

  • 47. Development of Neonatal T4 assay for congenital hypothyroidism screening using automated GSP system

Hiekkanen A.

  • 48. Development of Neonatal hTSH assay for congenital hypothyroidisms screening using automated GSP system

Hiekkanen A.

  • 49. Congenital hypothyroidism (CH) in Moscow city: the results of neonatal screening for 2008 year

Mitkina V.

  • 50. Biochip array technology for measurement of thyrotropin in dried blood spots

Parlato G.

  • 51. The Bulgarian Neonatal Thyroid Screening (NTS) Programme 1993–2008

Stoeva I.

SESSION 4:

NEWBORN SCREENING FOR CONGENITAL ADRENAL HYPERPLASIA

  • 52. The ISNS 17OHP Initiative: Establishing of 17OHP cut-off levels by international collaboration

Blankenstein O.

  • 53. Newborn screening for congenital adrenal hyperplasia (CAH) by steroid profile analysis using turbulent flow chromatography by tandem mass spectrometry without acetonitrile

Matern D.

  • 54. Proficiency testing for second tier CAH screening: towards harmonization of results

Mei J.

  • 55. Prevalence and clinical features of congenital adrenal hyperplasia (CAH) in a multiethnic population without newborn screening

Knowles R. L.

  • 56. Newborn screening for congenital adrenal hyperplasia in the Czech Republic: evaluation of the first 28 months reveals one false negative case

Votava F.

POSTERS

  • 57. Demonstration of increased throughput with automated multiplexed immunoassays for newborn screening

Sorette M.

  • 58. Congenital adrenal hyperplasia as cause of sudden infant death – argument for neonatal screening

Strnadova K.

SESSION 5:

NEWBORN SCREENING FOR CYSTIC FIBROSIS

  • 59. Activity and Consensus of European Cystic Fibrosis Society working group of neonatal screening for cystic fibrosis

Castellani C.

  • 60. Cystic fibrosis: 7 years of neonatal screening in Catalonia

Marin J. L.

  • 61. Cystic fibrosis heel prick among a newborn population in the Netherlands: the CHOPIN-study

Vernooij-van Langen A.

  • 62. Newborn screening for cystic fibrosis in England in 2007–2008

Sinclair D.

  • 63. Biochemical strategy IRT/PAP in newborn screening for cystic fibrosis

Stopsack M.

  • 64. The effectiveness of a combined immunoreactive trypsin (IRT)/pancreatitis-associated protein (PAP)/DNA newborn screening strategy for cystic fibrosis

Ranieri E.

POSTERS

  • 65. Pilot study of newborns screening for cystic fibrosis in Serbia

Grkovic S.

  • 66. Development of an updated Neonatal AutoDELFIA IRT assay (B005-212) for cystic fibrosis screening

Kerokoski P.

  • 67. The decision making process leading towards implementation of a nationwide newborn screening for cystic fibrosis in the Czech Republic

Skalicka V.

  • 68. Evaluation study for neonatal screening of cystic fibrosis: comparison between two different Delfia Neonatal IRT kits

Tamanini A.

  • 69. Pancreatitis-associated protein in CF screening

Vernooij-van Langen A.

SESSION 6:

EUROPEAN NEWBORN SCREENING: REPORTS BY COUNTRY

  • 70. European newborn screening survey

Loeber J. G.

  • 71. Newborn screening for phenylketonuria in Bulgaria – past, present and future

Sinigerska I.

  • 72. Neonatal screening program for congenital hypothyroidism in Armenia

Tovmasyan I.

  • 73. PKU and congenital hypothyroidism screening in east region of Ukraine

Grechanina O.

  • 74. National newborn screening in Slovakia

Knapkova M.

  • 75. Newborn screening in Szeged, Hungary

Karg E.

  • 76. Expanded newborn screening in Norway; advisory report from a national working group

Klingenberg C.

  • 77. Four years of expanded newborn screening in Portugal

Vilarinho L.

  • 78. Expanded neonatal screening program in the Netherlands: results and some pitfalls

Elvers B.

POSTERS

  • 79. Challenges for NBS in emerging countries: is it possible for a NBS program to be better than the health system that carries it out?

Botler J.

  • 80. Evaluation of 3-year application of the enzymatic colorimetric phenylalanine assay in the setting of neonatal screening for phenylketonuria in Serbia

Grkovic S.

  • 81. Neonatal screening and prevention of the congenital malformation in Saratov region

Gumenuyk O.

  • 82. The efficiency of neonatal screening in Saratov region

Gumenuyk O.

  • 83. Selective metabolic screening base for introduction of expanded newborn screening for inherited metabolic diseases

Ivanova M.

  • 84. Newborn screening by tandem mass spectrometry in Lebanon: 2 years experience

Khneisser I.

  • 85. Audit of the neonatal screening programme in Estonia

Muru K.

  • 86. Outcome of newborn screening program in the Kingdom of Saudi Arabia

Rahbeeni Z.

SESSION 7:

NEWBORN SCREENING IN USA AND EUROPE: DEVELOPING A EUROPEAN CONSENSUS SCREENING PANEL

  • 87. Newborn screening (NBS) in the United States: decision making about the NBS panels

Howell R. R.

SESSION 8:

MISCELLANEOUS TOPICS

  • 88. Psychological effects of false positive results in CF newborn screening: a 2 years follow-up

Roussey M.

  • 89. Ascertaining parental consent to storage of newborn bloodspot cards

Mackenzie J.

  • 90. A high frequency of private mutations in the Swedish galactosemia population

Ohlsson A.

  • 91. Newborn screening for sickle cell disease in France

Bardakdjian-Michau J.

  • 92. Newborn screening for sickle cell disease using tandem mass spectrometry

Boemer F.

  • 93. Results of the first year of universal neonatal screening for sickle cell disease in the Netherlands

Bouva M.

  • 94. Evaluation of nine years AABR hearing screening in Dutch NICU’s

Verkerk P. H.

POSTERS

  • 95. Newborn screening long-term follow up – case study: Improving outcome for PKU use of drug Tx with diet liberalization

Adams J.

  • 96. Education about newborn screening dried bloodspot tests. A programme to improve the quality of dried blood spots and improve the knowledge of staff taking the specimen

Asplin D.

  • 97. Evaluation of the neonatal screening for sickle cell disease using the adapted integration software for Variant Newborn Screening System

Bouva M.

  • 98. Detection at birth of hearing-impaired children

Dauman R.

  • 99. Early detection of sickle cell anemia and others hemoglobinopathies in neonates in the Basque country. Pilot study in anonymous not related population

Espada M.

  • 100. MALDI-TOF-MS based screening test for newborn detection of sickle cell disease: what throughput for what results

Hachani J.

  • 101. Automated instrument for dried blood spot assays

Furu P.

  • 102. False results in newborn bloodspot screening

Hall K.

  • 103. Development of a new galactose kit from Ani Labsystems

Hao W.

  • 104. Extended immunoassay for hemoglobinopathy screening: moving further with a true screening assay

Huhtinen P.

  • 105. A case for mandatory expanded screening

John K.

  • 106. Improved total galactose assay for galactosemia screening in newborns

Karvonen H.

  • 107. A pilot newborn screening programme for congenital toxoplasmosis in the Republic of Ireland

Mayne P.

  • 108. Comparison of different filter papers for the use in newborn screening

Müller C.

  • 109. A novel software algorithm for the quantitative calculation of mass spectral ion intensities for inborn errors of metabolism

Nagtalon D.


Štítky
Neonatologie Pediatrie Praktické lékařství pro děti a dorost

Článek vyšel v časopise

Česko-slovenská pediatrie

Číslo 4

2009 Číslo 4

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Zánětlivá bolest zad a axiální spondylartritida – Diagnostika a referenční strategie
nový kurz
Autoři: MUDr. Monika Gregová, Ph.D., MUDr. Kristýna Bubová

Inhibitory karboanhydrázy v léčbě glaukomu
Autoři: as. MUDr. Petr Výborný, CSc., FEBO

Příběh jedlé sody
Autoři: MUDr. Ladislav Korábek, CSc., MBA

Krvácení v důsledku portální hypertenze při jaterní cirhóze – od pohledu záchranné služby až po závěrečný hepato-gastroenterologický pohled
Autoři: PhDr. Petr Jaššo, MBA, MUDr. Hynek Fiala, Ph.D., prof. MUDr. Radan Brůha, CSc., MUDr. Tomáš Fejfar, Ph.D., MUDr. David Astapenko, Ph.D., prof. MUDr. Vladimír Černý, Ph.D.

Rozšíření možností lokální terapie atopické dermatitidy v ordinaci praktického lékaře či alergologa
Autoři: MUDr. Nina Benáková, Ph.D.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se